<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512847</url>
  </required_header>
  <id_info>
    <org_study_id>REG-006-2018</org_study_id>
    <nct_id>NCT03512847</nct_id>
  </id_info>
  <brief_title>Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims include:&#xD;
&#xD;
        -  Exploring potential predictive molecular profiles to immunotherapy/chemotherapy&#xD;
&#xD;
        -  Investigating the role of circulating tumor DNA as a dynamic biomarker during&#xD;
           immunotherapy/chemotherapy&#xD;
&#xD;
        -  Identifying possible resistance mechanisms to immunotherapy/chemotherapy&#xD;
&#xD;
      Materials and methods:&#xD;
&#xD;
      Approximately 150 patients diagnosed with metastatic NSCLC assigned for immunotherapy or&#xD;
      chemotherapy will be candidates for inclusion during a 1-2 years period.&#xD;
&#xD;
      A comprehensive molecular profiling will be made from the diagnostic biopsy. Before every&#xD;
      treatment-cycle a blood sample will be taken to quantify ctDNA. At time of progressive&#xD;
      disease during/after first line treatment, patients will be asked to participate in a new&#xD;
      biopsy and a comprehensive molecular profiling will be performed.&#xD;
&#xD;
      The tissue and blood samples collected will be stored in a biobank. Clinical data will be&#xD;
      collected to perform a comprehensive database.&#xD;
&#xD;
      Analysis:&#xD;
&#xD;
      Potentially predictive molecular profiles for immunotherapy/chemotherapy will be found by&#xD;
      comparison of treatment outcome for patients with specific molecular characteristics.&#xD;
&#xD;
      Through quantification of ctDNA during treatment and upon progression, the role of ctDNA as a&#xD;
      dynamic biomarker will be further strengthened.&#xD;
&#xD;
      Differences in molecular profiles pre- and post-treatment may reveal resistance mechanisms to&#xD;
      treatment. Molecular profiling on progression can be valuable in second-line treatment&#xD;
      guidance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive gene profiles</measure>
    <time_frame>until progression or death, an average of 3 years</time_frame>
    <description>Concordance between specific gene profiles and treatment outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resistance mechanisms toward chemotherapy and immunotherapy</measure>
    <time_frame>until progression or death, an average of 3 years</time_frame>
    <description>Differences in molecular profiles pre- and post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ctDNA as a dynamic biomarker</measure>
    <time_frame>until progression or death, an average of 3 years</time_frame>
    <description>Quantification of ctDNA during treatment linked to treatment outcome</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metastatic Nonsmall Cell Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Comprehensive molecular profiling. Whole Exome Sequencing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Metastatic non-small cell lung cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Able to understand and read Danish&#xD;
&#xD;
          -  WHO Performance status 0-2&#xD;
&#xD;
          -  Acceptable organ function (liver/kidney/heart) for treatment&#xD;
&#xD;
          -  The disease has to be:&#xD;
&#xD;
        evaluable or measurable according to RECIST/iRECIST accessible for biopsy metastatic or not&#xD;
        suitable for curative intended treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other active cancers&#xD;
&#xD;
          -  Contraindications for systemic therapy&#xD;
&#xD;
          -  ALK-positive, ROS-1 or EGFR mutations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank S Malene, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Zeland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Naestved</city>
        <state>Zealand</state>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liquid biopsy</keyword>
  <keyword>genomic profiling</keyword>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

